Pfizer Seeks Approval for Booster Shots in Adolescents Aged 16-17

Story Highlights
  • Pfizer approaches US authorities for approval of booster dose administration.
  • This decision stems from the increased transmissibility of potentially threatful Omicron.
  • FDA approved booster doses for adults above 18 years so far.

Washington: Pfizer on Tuesday announced to seek approval from authorities in the Senate for booster shot among adolescents as the fear of Omicron variant severed normal life. “Today, we submitted a request to the @US_FDA to expand the emergency use authorization of a booster dose of our COVID-19 vaccine to include 16- and 17-year-olds,” Pfizer CEO Albert Bourla informed through twitter.

So far the FDA has granted Emergency Use Authorization for booster shots in individuals aged 18 and over, which could be administered six months after the primary series of the Pfizer or Moderna Covid vaccine, or two months after the Johnson & Johnson shot.

As the fear of the spread of the ferocious variant takes over economies, experts across the world are trying to study the pattern of mutations, its symptoms and transmissibility which forms the foundation for setting precautionary norms.

Although 200 cases of infection have been detected across several nations, USA has so far reported zero infection attributed to Omicron whereas Delta Variant accounts for more than 99per cent of all infections.

Earlier on Tuesday, Moderna CEO raised alert speculating efficacy of existing vaccines against the new mutation.

Related Articles

Back to top button